Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People with locally advanced breast cancer that started in the breast, or breast cancer that has come back in the same area, with or without spread to other parts of the body (if the cancer has spread, it must be stable or limited to a small number of areas)
- People whose doctors have determined they need high-dose radiotherapy to manage the cancer in the long term
- People who are physically and mentally well enough to receive high-dose radiotherapy
- People whose tumour can be reached safely with a needle injection directly into it
- People who are able to undergo MRI scans as part of the study protocol
- People with at least one tumour that measures between 30mm and 150mm (3cm to 15cm) as seen on ultrasound or MRI
- People with a life expectancy of 12 months or more
- Women who could become pregnant must have a negative pregnancy test before radiotherapy starts, and must be willing to use contraception from the time of consent until 3 months after radiotherapy ends
- People who have given written consent to participate in the trial
Who may not be able to join:
- People who have previously had radiotherapy to the same area being treated in this trial
- People whose tumour measures less than 30mm or more than 150mm on ultrasound or MRI
- People whose tumour is located near major blood vessels or nerves (such as the brachial plexus), making it unsafe to inject directly into it
- People currently receiving certain cancer treatments at the same time as radiotherapy — some treatments are permitted (including Herceptin, Pertuzumab, Denosumab, hormone therapies, and bisphosphonates), but other chemotherapy or biological therapies must be stopped at least 3 weeks before radiotherapy begins
- People who are pregnant or currently breastfeeding
- People who have had an allergic reaction to any ingredient in the study drug (KORTUC)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Navita Somaiah, The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Phone: +44(0)2086613460
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete tumour response based on best response assessed by contrast enhanced MRI according to criteria outlined in Section 3.2.1 of the trial protocol, performed up to and including 12 months post radiotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.